Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study

Objective. Clozapine is the current gold standard treatment for severe treatment-refractory schizophrenia, but even so 40 - 70% of these patients will continue to experience disabling symptoms when treated with clozapine monotherapy. Current clinical practice at Stikland Hospital holds that known cl...

Full description

Bibliographic Details
Main Authors: L Koen, C E van den Berg, D J H Niehaus
Format: Article
Language:English
Published: AOSIS 2008-12-01
Series:South African Journal of Psychiatry
Online Access:http://www.sajp.org.za/index.php/sajp/article/view/174
_version_ 1818246592409370624
author L Koen
C E van den Berg
D J H Niehaus
author_facet L Koen
C E van den Berg
D J H Niehaus
author_sort L Koen
collection DOAJ
description Objective. Clozapine is the current gold standard treatment for severe treatment-refractory schizophrenia, but even so 40 - 70% of these patients will continue to experience disabling symptoms when treated with clozapine monotherapy. Current clinical practice at Stikland Hospital holds that known clozapine-refractory schizophrenia patients who relapse due to non-compliance are treated with an initial combination of clozapine and ECT (if able to consent) when readmitted. The purpose of this study was to evaluate the validity of this practice. Methods. Patients were divided into an ECT (EG) and non-ECT (CG) group. Clozapine was started and ECT administered as per protocol. Demographic data, psychiatric and medication history and data concerning adverse events were collected. Positive and Negative Symptom Scale (PANSS) scores were done at baseline and at days 21 and 42. Results. At discharge, although numerically the average increase in clozapine dose was lower and the reduction in length of stay was greater in the EG, none of the variables measured were statistically significantly different between groups. More concomitants were also used in the EG. Conclusions. This pilot study represents the first controlled trial of ECT-clozapine bitherapy in a population with clozapine- refractory schizophrenia and schizoaffective disorder reported in the literature. The validity of our choice of current clinical practice in this population was not supported by our results. However, the study did provide us with preliminary evidence for the safety and efficacy of this combination. It would therefore be reasonable to continue to use this strategy in selected cases, at least until other clozapine-refractory treatment strategies become more available in our setting.
first_indexed 2024-12-12T14:51:16Z
format Article
id doaj.art-ca4738f133ec4b188bf601d95d71cb27
institution Directory Open Access Journal
issn 1608-9685
2078-6786
language English
last_indexed 2024-12-12T14:51:16Z
publishDate 2008-12-01
publisher AOSIS
record_format Article
series South African Journal of Psychiatry
spelling doaj.art-ca4738f133ec4b188bf601d95d71cb272022-12-22T00:21:00ZengAOSISSouth African Journal of Psychiatry1608-96852078-67862008-12-0114410.4102/sajpsychiatry.v14i4.174181Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot studyL KoenC E van den BergD J H NiehausObjective. Clozapine is the current gold standard treatment for severe treatment-refractory schizophrenia, but even so 40 - 70% of these patients will continue to experience disabling symptoms when treated with clozapine monotherapy. Current clinical practice at Stikland Hospital holds that known clozapine-refractory schizophrenia patients who relapse due to non-compliance are treated with an initial combination of clozapine and ECT (if able to consent) when readmitted. The purpose of this study was to evaluate the validity of this practice. Methods. Patients were divided into an ECT (EG) and non-ECT (CG) group. Clozapine was started and ECT administered as per protocol. Demographic data, psychiatric and medication history and data concerning adverse events were collected. Positive and Negative Symptom Scale (PANSS) scores were done at baseline and at days 21 and 42. Results. At discharge, although numerically the average increase in clozapine dose was lower and the reduction in length of stay was greater in the EG, none of the variables measured were statistically significantly different between groups. More concomitants were also used in the EG. Conclusions. This pilot study represents the first controlled trial of ECT-clozapine bitherapy in a population with clozapine- refractory schizophrenia and schizoaffective disorder reported in the literature. The validity of our choice of current clinical practice in this population was not supported by our results. However, the study did provide us with preliminary evidence for the safety and efficacy of this combination. It would therefore be reasonable to continue to use this strategy in selected cases, at least until other clozapine-refractory treatment strategies become more available in our setting.http://www.sajp.org.za/index.php/sajp/article/view/174
spellingShingle L Koen
C E van den Berg
D J H Niehaus
Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
South African Journal of Psychiatry
title Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
title_full Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
title_fullStr Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
title_full_unstemmed Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
title_short Combining ECT and clozapine in the treatment of clozapine-refractory schizophrenia and schizoaffective disorder – a pilot study
title_sort combining ect and clozapine in the treatment of clozapine refractory schizophrenia and schizoaffective disorder a pilot study
url http://www.sajp.org.za/index.php/sajp/article/view/174
work_keys_str_mv AT lkoen combiningectandclozapineinthetreatmentofclozapinerefractoryschizophreniaandschizoaffectivedisorderapilotstudy
AT cevandenberg combiningectandclozapineinthetreatmentofclozapinerefractoryschizophreniaandschizoaffectivedisorderapilotstudy
AT djhniehaus combiningectandclozapineinthetreatmentofclozapinerefractoryschizophreniaandschizoaffectivedisorderapilotstudy